South Korea has agreed to buy 10 million doses of a new COVID-19 vaccine, developed at the University of Washington School of Medicine. uwmnewsroom UWMedicine
A COVID-19 vaccine, developed at the University of Washington School of Medicine, has been proven safe and effective in late-stage clinical testing.
SK Bioscience has developed vaccines since 2008, with the cell-cultured trivalent flu vaccine in 2015, followed by the cell-cultured quadrivalent flu vaccine, the zoster vaccine, and the varicella vaccine. In 2020, the company pivoted into the global market with the development of the COVID-19 vaccine.
“The advantage of the nanoparticle vaccine over a traditional protein subunit vaccine is that, by presenting the antigen in this repetitive array, you will elicit a stronger immune response, which should translate to better protection,” saidKing also stressed that a protein nanoparticle vaccine will be easier to produce and store. It’s effective at low doses and simple to make on a large scale while not requiring deep freezing in order to become stable.
“We know we have more than 2 billion people worldwide that have not received a single dose of vaccine,” saidIf our vaccine is distributed through COVAX, it will allow it to reach these people that need to have access to doses.”